Paclitaxcel

Phase 2Cell therapy

SShanghai Jiao Tong University School of Medicine

Paclitaxcel is one of 9 small molecule programs targeting Triple Negative Breast Cancer (TNBC). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Triple Negative Breast Cancer (TNBC)Recruiting

Triple Negative Breast Cancer (TNBC)Phase 2

Recruiting

Competition

Competitive Landscape

12 competitors in Triple Negative Breast Cancer (TNBC)

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

4 2

Taxol

Teva

Phase 2

1 3

PD-1 Monoclonal Antibody

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

1 4

BL-B01D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

1 5

Paraplatin

AAvyxa

Phase 2

2 6

Retlirafusp Alfa

TTang-Du Hospital

Phase 2

1 7

Yervoy

Bristol-Myers Squibb

Preclinical

1 8

Paclitaxcel

SShanghai Jiao Tong University School of Medicine

Phase 2

1 9

Breakvax

BBreakBio Corp

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 2Recruiting

Triple Negative Breast Cancer (TNBC)

NCT07743190

Clinical

Trials by Indication[1]

Oral Squamous Cell Carcinoma1 trial

Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients

Completed·SShanghai Jiao Tong University School of Medicine·Phase 1·NCT04473716·20 enrolled

Triple Negative Breast Cancer (TNBC)1 trial

NeoTILs: A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)

Recruiting·MMedical University of South Carolina·Phase 2·NCT07743190·55 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Paclitaxcel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Paclitaxcel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Paclitaxcel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Jiao Tong University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: SShanghai Jiao Tong University School of Medicine

Paclitaxcel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Oral Squamous Cell Carcinoma1 trial

Triple Negative Breast Cancer (TNBC)1 trial

References

Drug Info

Quick Facts

Related News